Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 13/20 | 0.60 |
| ▸ | TP53 | P04637 | 9/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcium SCHEMBL29917796 | 0.98 | LMNA (0.65) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL4279959 | 0.97 | LMNA (0.67) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL12284690 | 0.88 | HSD17B10 (0.63) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL4114434 | 0.87 | HTR7 (0.67) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL8311251 | 0.86 | HTR7 (0.65) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL8318327 | 0.86 | HTR7 (0.65) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL11530731 | 0.86 | LMNA (0.58) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL2970063 | 0.84 | HSD17B10 (0.81) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL5016354 | 0.84 | HTR7 (0.67) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 | |
| SCHEMBL11533902 | 0.83 | LMNA (0.55) | LMNAHSD17B10CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096773-A1 | FABP7 INHIBITORS FOR THE TREATMENT OF IMMUNOTHERAPY RESISTANT TUMORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-118667897-A | Method for synthesizing isochromanone compound by oxidizing [4+2] cyclization by using multi-copper oxidase | 南京工业大学 | 2024-09-20 | — | — | CN | disclosed |
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-108203438-B | Fused imidazole compounds having indoleamine 2,3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | KING ABDULAZIZ UNIVERSITY (SA) | 2020-03-03 | — | — | US | disclosed |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | KING ABDULAZIZ UNIVERSITY (SA) | 2020-03-03 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HUNTER-FLEMING LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| US-4210590-A | WITH BORANE COMPLEX REAGENT IN PRESENCE OF TRIFLUOROACETIC ACID | MCNEIL LABORATORIES, INCORPORATED (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | LMNA 4703/4885HSD17B10 1745/4885CYP1A2 295/4885 |
| US-20080146644-A1 | Tricyclic Cytoprotective Compounds | HCRTR1, CDR2, MSR1 | LMNA 4148/4885HSD17B10 1383/4885CYP1A2 2596/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | LMNA 4436/4885HSD17B10 678/4885CYP1A2 171/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | LMNA 4738/4885HSD17B10 1268/4885CYP1A2 130/4885 |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | FLI1, ABL1, INMT | LMNA 2876/4885HSD17B10 3958/4885CYP1A2 1146/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | LMNA 4436/4885HSD17B10 678/4885CYP1A2 171/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | LMNA 4148/4885HSD17B10 1383/4885CYP1A2 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.